Loading...
XHKG
1681
Market cap1.61bUSD
Dec 05, Last price  
14.73HKD
1D
-0.47%
1Q
-8.79%
Jan 2017
281.61%
IPO
212.08%
Name

Consun Pharmaceutical Group Ltd

Chart & Performance

D1W1MN
XHKG:1681 chart
P/E
12.49
P/S
3.83
EPS
1.07
Div Yield, %
4.07%
Shrs. gr., 5y
-0.53%
Rev. gr., 5y
11.42%
Revenues
2.97b
+14.56%
457,801,000571,765,000730,683,000831,108,0001,223,488,0001,660,230,0001,843,973,0001,728,256,0001,752,830,0002,044,660,0002,339,650,0002,590,115,0002,967,235,000
Net income
910m
+16.05%
136,206,000152,882,000211,200,000249,689,000307,526,000396,242,000465,353,00079,820,000498,788,000590,172,000682,907,000784,534,000910,458,000
CFO
1.09b
+32.73%
128,832,000163,610,000294,721,000184,043,000449,177,000252,123,000754,210,000383,315,000867,058,000725,537,000947,679,000818,973,0001,086,987,000
Dividend
Jun 10, 20250.3 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
IPO date
Dec 19, 2013
Employees
3,009
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT